| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10013568 | HBV | ENSG00000151617.17 | protein_coding | EDNRA | No | No | 1909 | P25101 |
| TVIS20026127 | HPV | ENSG00000151617.17 | protein_coding | EDNRA | No | No | 1909 | P25101 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | EDNRA |
|---|---|
| DrugBank ID | DB06403 |
| Drug Name | Ambrisentan |
| Target ID | BE0000521 |
| UniProt ID | P25101 |
| Regulation Type | antagonist |
| PubMed IDs | 20811346; 19389876; 19601701; 19920913 |
| Citations | Spence R, Mandagere A, Richards DB, Magee MH, Dufton C, Boinpally R: Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010 Oct;88(4):513-20. doi: 10.1038/clpt.2010.120. Epub 2010 Sep 1.@@Richards DB, Walker GA, Mandagere A, Magee MH, Henderson LS: Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol. 2009 Jun;49(6):719-24. doi: 10.1177/0091270009335870. Epub 2009 Apr 23.@@Kingman M, Ruggiero R, Torres F: Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2009 Aug;10(11):1847-58. doi: 10.1517/14656560903061275.@@Casserly B, Klinger JR: Ambrisentan for the treatment of pulmonary arterial hypertension. Drug Des Devel Ther. 2009 Feb 6;2:265-80. |
| Groups | Approved; Investigational |
| Direct Classification | Diphenylmethanes |
| SMILES | COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1 |
| Pathways | |
| PharmGKB | PA165860521 |
| ChEMBL | CHEMBL1111 |
